Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage
MT Newswires Live
Apr 22
Nyrada (ASX:NYR) confirmed that the Nepean Hospital in New South Wales was activated as the first site in its Protect-MI phase 2a clinical trial assessing Xolatryp in potentially reducing myocardial injury, or damage to the heart muscle cells, in patients suffering a heart attack, according to a Wednesday Australian bourse filing.
The trial's primary endpoint is the safety/tolerability of the drug candidate, the filing said. Several secondary efficacy endpoints are also being evaluated, including cardiac function, extent of cardiac injury, biomarkers such as Troponin I levels, and the incidence of arrhythmias of interest.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.